Key result
Selective thromboxane synthase inhibition improved one-week prosthetic graft patency to 81% compared with 46% in untreated dogs, comparable to conventional cyclooxygenase inhibition.
Why the study?
Does selective thromboxane synthase inhibition or cyclooxygenase inhibition improve arterial graft patency and reduce platelet deposition in dogs undergoing carotid artery replacement?
Does selective thromboxane synthase inhibition or cyclooxygenase inhibition improve arterial graft patency and reduce platelet deposition in dogs undergoing carotid artery replacement?
Answers are grounded in this paper and cite their sources.
Selective thromboxane synthase inhibition improves small-caliber prosthetic graft patency to a similar extent as conventional cyclooxygenase inhibition in a canine model.
This study examined the effect of selective thromboxane synthase inhibition and nonselective cyclooxygenase inhibition on vascular graft patency and indium 111-labeled platelet deposition in 35 mongrel dogs undergoing carotid artery replacement with 4 mm X 4 cm polytetrafluoroethylene (PTFE) (one side) and Dacron (opposite side) end-to-end grafts. Aspirin-dipyridamole therapy improved one-week graft patency, from 46% in untreated dogs to 93% in treated dogs. Thromboxane synthase inhibition (U-63557A) improved graft patency in these dogs to 81%. Both drug treatments reduced platelet deposition on Dacron and PTFE grafts by 48% to 68% compared with control dogs. Dacron grafts accumulated significantly more platelets than PTFE grafts but had comparable patency rates. Low-dose aspirin therapy had no significant effect on either graft patency or platelet deposition. All treatment groups showed a 60% to 76% reduction in serum thromboxane B2, but only thromboxane synthase inhibitor treatment increased plasma 6-keto-prostaglandin F1 alpha by 100%. Selective thromboxane synthase inhibition improved small-caliber prosthetic graft patency to the same extent as did conventional cyclooxygenase inhibition in this preliminary study.
No takes yet. Share an insight, caveat, or question.
Martha D. McDaniel (1987) studied carotid artery replacement (n=35). Thromboxane synthase inhibition (U-63557A) vs. Untreated control was evaluated on One-week graft patency. Selective thromboxane synthase inhibition improved one-week prosthetic graft patency to 81% compared with 46% in untreated dogs, comparable to conventional cyclooxygenase inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: